Unknown

Dataset Information

0

Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models.


ABSTRACT: Limb-girdle muscular dystrophy type 2B (LGMD2B) is caused by mutations in the dysferlin gene, resulting in non-functional dysferlin, a key protein found in muscle membrane. Treatment options available for patients are chiefly palliative in nature and focus on maintaining ambulation. Our hypothesis is that galectin-1 (Gal-1), a soluble carbohydrate binding protein, increases membrane repair capacity and myogenic potential of dysferlin-deficient muscle cells and muscle fibers. To test this hypothesis, we used recombinant human galectin-1 (rHsGal-1) to treat dysferlin-deficient models. We show that rHsGal-1 treatments of 48 h-72 h promotes myogenic maturation as indicated through improvements in size, myotube alignment, myoblast migration, and membrane repair capacity in dysferlin-deficient myotubes and myofibers. Furthermore, increased membrane repair capacity of dysferlin-deficient myotubes, independent of increased myogenic maturation is apparent and co-localizes on the membrane of myotubes after a brief 10min treatment with labeled rHsGal-1. We show the carbohydrate recognition domain of Gal-1 is necessary for observed membrane repair. Improvements in membrane repair after only a 10 min rHsGal-1treatment suggest mechanical stabilization of the membrane due to interaction with glycosylated membrane bound, ECM or yet to be identified ligands through the CDR domain of Gal-1. rHsGal-1 shows calcium-independent membrane repair in dysferlin-deficient and wild-type myotubes and myofibers. Together our novel results reveal Gal-1 mediates disease pathologies through both changes in integral myogenic protein expression and mechanical membrane stabilization.

SUBMITTER: Vallecillo-Zuniga ML 

PROVIDER: S-EPMC7470338 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications


Limb-girdle muscular dystrophy type 2B (LGMD2B) is caused by mutations in the dysferlin gene, resulting in non-functional dysferlin, a key protein found in muscle membrane. Treatment options available for patients are chiefly palliative in nature and focus on maintaining ambulation. Our hypothesis is that galectin-1 (Gal-1), a soluble carbohydrate binding protein, increases membrane repair capacity and myogenic potential of dysferlin-deficient muscle cells and muscle fibers. To test this hypothe  ...[more]

Similar Datasets

| S-EPMC7565960 | biostudies-literature
| S-EPMC5240545 | biostudies-literature
| S-EPMC8741482 | biostudies-literature
| S-EPMC4079937 | biostudies-literature
| S-EPMC1904311 | biostudies-literature
| S-EPMC2856642 | biostudies-literature
| S-EPMC4230592 | biostudies-literature
| S-EPMC4101652 | biostudies-literature
| S-EPMC3774516 | biostudies-literature
| S-EPMC7352960 | biostudies-literature